Back to top

Analyst Blog

Boston Scientific’s (BSX - Analyst Report) coronary stent portfolio was boosted with the CE Mark approval of its Synergy everolimus-eluting platinum chromium stent. The product features everolimus drug coating which dissolves in three months, thus improving post-implant vessel healing. This eliminates exposure to polymer over a long-term period, which is a possible cause of adverse events at a late stage.

The CE Mark approval of Synergy was backed by positive data from the six-month EVOLVE study demonstrating its non-inferiority to the Promus Element stent with respect to in-stent late loss. Subsequently, Boston Scientific plans to initiate a limited market release of the Synergy stent by early 2013, while the commercial launch is slated for early 2014. While the stent is yet to receive approval in the US or Japan, enrollment in the EVOLVE II trial is expected to begin later this year. Data from this trial, which will enroll 1,684 patients across 160 sites globally, will be used to gain approvals in these two regions.

While we are encouraged with the approval of Synergy in Europe, Boston Scientific’s Interventional Cardiology segment has been recording declining sales over the past few quarters primarily owing to disappointing performance of the coronary stent franchise. This is significant as the company in the recently reported third quarter derived 17% of its total revenues from coronary stents.

During the recently reported third quarter, global sales of coronary stent system declined 24.4% to $304 million due to disappointing performances from both drug-eluting stents (“DES”) that declined 24.5% to $283 million and bare-metal stents that plunged 22.2% to $21 million. The company’s DES business in the US has been struggling due to several headwinds – lower pricing, softness in percutaneous interventional volume and share losses following the launch of Medtronic’s (MDT - Analyst Report) Resolute Integrity stent.

Given the several headwinds currently at play, Boston Scientific continues to focus on strategic initiatives to drive growth and profitability. These include strengthening its portfolio, targeting suitable acquisitions in areas of unmet medical needs and focus on emerging markets. The company also plans to invest approximately $150 million in China, one of the world’s fastest growing and largest medical devices markets, over the next 5 years to build a local manufacturing operation. We are impressed with Boston Scientific’s recent acquisitions of Rhythmia Medical and BridgePoint Medical, which reflects its focus on new therapies to drive top line.

We expect these factors to benefit the company over the long term and as such we have a ‘Neutral’ recommendation on Boston Scientific. The stock retains a Zacks #3 Rank (“Hold”) in the short term.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%